A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of Type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 7, 2000, Pages 1455-1467

  Moses, Robert ^a  

^a Department of Endocrinology ^*  (Australia)

Author keywords

Prandial glucose; Repaglinide; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; PIPERIDINE DERIVATIVE; REPAGLINIDE;

BLOOD; CLINICAL TRIAL; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; POSTPRANDIAL STATE; REVIEW;

BLOOD GLUCOSE; CARBAMATES; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; PIPERIDINES; POSTPRANDIAL PERIOD;

EID: 0034572838     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.7.1455     Document Type: Article

References (52)

1. O-RAHILLY s, HATTERSLEY A, VAAG A, GRAY H: insulin resistance as the major, cause of impaired glucose tolerance: a self-fulfilling prophesy? Lancet (1994) 344:585-589.
2. POLONSKY KS, GIVEN BD, HIRSCH LJ et al,-. Abnormal patterns of insulin secretion In non-insulindependent diabetes mellitus. W. Engt. J. Mod. (1988) 318:1231->239.
3. COATES PA, OLLERTON RL, LUZIO SD, ISMAIL I, OWENS DR: A glimpse of the 'natural history' of established Type 2 (non-Insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res, Clin. Pract, (1994) 26:177-187.
4. CREPALDI G, DEL PRATO S: What therapy do our N1DDM patients need? Insulin releasers. Diabetes Res. Clin. Pract. (1995) 28(Suppl.):Sl 59-165.
5. OWENS DR, LUZIO SD, COATES PA: Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK- Diabet. Mcd. (1996) 13(Suppl. 6):S19-24.
6. GERICH JE: Metabolic abnormalities in impaired glucose tolerance. Metabolism (1997) 46:40-43.
7. MITRAKOU A, KELLEY D, VENEMAN T et al.: Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycaemia in NIDDM. Diabetes (1990) 39:1381-1390.
8. BRUTTOMESSO D, PIANTA A, MARI A et al.: Restoration of early rise in plasma Insulin levels improves the glucose tolerance of Type 2 diabetic patients. Diabetes (1999) 48:99-105.
9. HOME PD: Rapid-acting insulin secretagogues: a clinical need? Exp. Clin. Endocrinol. Diabetes (1999) 107(Suppl. 4):S115-119-
10. GREENFIELD M, KOLTERMAN O, OLEFSKY JM, REAVEN GM: The effect of ten days of fasting on various aspects of carbohydrate metabolism in obese diabetic subjects with significant fasting hyperglycemia. Metabolism (1978) 12(Suppl. 2):1839-1852.
11. FELDER JP, MEYER HU, CURCHOD B, MAEDER E, PAHUD P, JEQUIER E: Effect of a 3-day fast on glucose storage and oxidation in obese hyperinsulinemic diabetics. Metabolism (1981) 30(2):184-189.
12. MELANDER A, DONNELLY R, RYDBERG T: Is there a concentration-effect relationship for sulphonylureas? Clin. Phannacokinct. (1998) 34:181-188.
13. FUHLENDORFF J, RORSMAN P, KOFOD H et al.-. Stimulation of insulin release by repaglinide and glibenclamidc involves both common and distinct processes. Diabetes (.1998) 47:345-351.
14. GILL GV, HUDDLE KR: Hypoglycaemic admissions among diabetic patients in Soweto, South Africa. Diabet. Med. (1993) 10:181-183.
15. ROBERTSON DA, HOME PD: Problems and pitfalls of sulphonylurea therapy in older patients. Dmgs Aging (1993) 3:510-524.
16. STAHL M, BERGER V: Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet. Med. (1999) 16:586-590.
17. CERIELLO A: The emerging role of post-prandial hyperglycaemlc spikes in the pathogcnesis of diabetic complications. Diabet. Med. (1998) 15:188-193-
18. HAFFNER SM: The importance of hyperglycaemia in the non-fasting state to the development of cardiovascular disease. Endocr. Rev. (1998) 19:583-592.
19. HALLER H: The clinical importance of postprandial glucose. Diabetes. Res. Clin. Pract. (1998) 40:S43i9.
20. LEFEBVRE PJ, SCHEEN AJ: The postprandial state and risk of cardiovascular disease. Diabet. Med. (1998) 15(Suppl. 4):S63-68.
21. HANEFELD M, FISCHERS, JULIUS U et ah. Riskfactors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabctologia (1996) 39:1577-1583-
22. DECODE STUDY GROUP, EUROPEAN DIABETES EPIDEMIOLOGY GROUP: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet (1999) 354:617-621.
23. TOMINAGA M, EGUCHI H, MANAKA H, IGARASHI K, KATO T, SEKIKAWA A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care (1999) 22:920-924.
24. GLATT M, SCHATZ H: The influence of an acyl-aminoalcyl-benzoic acid (HB 699) on biosynthesis and secretion of insulin in isolated rat islets of Langer hans. Diabete Metab. (1981) 7:105-108.
25. OWENS DR: Repaglinide - prandial glucose regulator: a new class of oral antidiabetic drug. Diabet. Med. (1998) 15(Suppl. 4):S28-36.
26. BOKVIST M, H0Y M, POULSEN CR, BUSCHARD K, GROMADA J: A4l66 but not repaglinide stimulate Ca2-evoked, KATP channel independent, secretion in rat pancreatic α- and β-cells. Dlabetologia (1998) 4l(Suppl. l):Abstract 543.
27. VINAMBRES C, VILLANUEVA-PENACARRILLO ML, VALVERDE I, MALAISSE VJ: Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets. Pbamtacol. Res. (1996) 34:83-85.
28. LOUCHAMI K, JIJAKLI H, SENER A, MALAISSE VJ: Effect of repaglinide upon nutrient metabolism, biosynthetic activity, cationic fluxes and insulin release in rat pancreatic islets. Res. Commun. Mol. Pathol. Pbannacol. (1998) 99:155-168.
29. BAKKALI-NADI A, MAILAISSE-LAGAE F, MALAISSE VJ: Insulinotropic action of meglitinide analogues; concentration-response relationship and nutrient dependency. Diabetes Res. (1994) 27:81-87.
30. OLIVER S, AHMAD S: Pharmacokinetics and bioavailability of repaglinide, a new oral antidiabetic agent for patients with Type 2 diabetes (NIDDM). Diabetologia (1997) 40(Suppl. 1):A320.
31. OWENS DR, LUZIO SD, ISMAIL I, BAYER T: Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with Type 2 diabetes. Diabetes Care (2000) 23:518-523.
32. SCHATZ H: Preclinical and clinical studies on safety and tolerability of repaglinide. Exp. Clin. Endocrinol. Diabetes (1999) 107(Suppl. 4):S144-S148.
33. HATORP V, HASSLACHER C, CLAUSON P: Pharmacokinetics of repaglinide in Type 2 diabetes patients with and without renal impairment. Diabetologia (1999) 42(Suppl. 1):A242.
34. RUCKLE JL, HATORP V: Repaglinide pharmacokinetics in patients with renal impairment versus healthy volunteers. Diabetologia (1998) 4l(Suppl. 1):A235.
35. SCHWARTZ SL, GOLDBERG RB, STRANGE P FOR THE REPAGLINIDE STUDY GROUP: Repaglinide in Type 2 diabetes: a randomized, double-blind, placebocontrolled, dose-response study. Diabetes (1998) 47(Suppl. 1):A98.
36. JOVANOVIC L, DAILEY G, HUANG W-C, STRANGE P, GOLDSTEIN B: Repaglinide in Type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. / Clin. Phannacol. (2000) 40:49-57.
37. VAN GAAL LF, VAN ACKER KL, DAMSBO P, DE LEEUWIH: Metabolic effects of repaglinide, a new oral hypoglycaemîc agent in therapy-naïve Type 2 diabetics. Diabetohgia (1995) 38(Suppl. 1):A43.
38. GOLDBERG RB, EINHORN D, LUCAS CP et a!.: A randomized placebo-controlled trial of repaglinide in the treatment of Type 2 diabetes. Diabetes Care (1998) 21:1897-1903.
39. DEJGAARD A, MADSBAD S, KILHOVD B, LAGER I, MUSTAJOKIP: Repaglinide compared to gliplzide in the treatment of Type 2 diabetic patients. Diabctohgia (1998) 4l(Suppl. 1):A236.
40. WOLFFENBUTTEL BH, LANDGRAF R: A 1-year multicenter randomized double-blind comparison of repaglinide and ghyburide for the treatment of Type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care (1999) 22(3):463-467.
41. MARBURY T, HUANG VC, STRANGE P, LEBOVITZ H: Repaglinide versus glyburidc: a one-year comparison trial. Diabetes. Res. Clin. Pract. (1999) 43:155-166.
42. LANDGRAF R, BILO HJ, MULLER PG: A comparison of repaglinide and glibenclamide in the treatment of Type 2 diabetic patients previously treated with sulphonylureas. Eiir. J. Clin. Pharmacol. (1999) 55(3):l65-171.
43. MOSES R, GOMIS R, BROWN FRANDSEN K, CLAUSON P: The efficacy and safety of repaglinide used as a flexible prandial glucose regulator in patients with Type 2 diabetes: a multi-centre, randomised, placebocontrolled, double-blind study. Diabct. Atcd. (1999) l6(Suppl. 1):95.
44. DAMSBO P, MARBUfiY TC, HATORP V, CLAUSON P, MÜLLER PG: Flexible prandial glucose regulation with repaglinide in patients with Type 2 diabetes. Diabetes Res. Clin. Pract. (1999) 45(l):31-39-
45. LANDGRAF R, BAUER C, SELENKA K, LEYCK DIEKEN M: Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes. Int. J. Obesity (2000) 24(Suppl. 3);S38-S44.
46. SMEDEGAARD KRISTENSEN J, BROWN FRANDSEN K, BAYER T, MÜLLER PG: Repaglinide treatment is associated with significantly less severe hypoglycaemic events compared to sulphonylureas. Diabetologia (1999) 42(Suppl. 1):A4.
47. NATTRASS M, LAURITZEN T: Prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? A review of the clinical evidence. Int. J. Obesity (2000) 24(Suppl. 3):S21-S31.
48. DAMSBO P, CLAUSON P, MARBURY TC, WINDFELD K: A double-blind randomized comparison of meal-related glycémie control by repaglinide and glyburide in well-controlled Type 2 diabetic patients. Diabetes Care (1999) 22(5):789-794.
49. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837-853-
50. MOSES R, SLOBODNIUK R, BOYAGES S et al.: Effect of repaglinide addition to metformin monotherapy on glycémie control in patients with Type 2 diabetes. Diabetes Care (1999) 22(1):119-124.
51. RASKIN P, JOVANOVIC L, BERGER S, SCHWARTZ S, VTOO V, RATNER R: Repaglinide/troglitazone combination therapy: improved glycémie control in Type 2 diabetes. Diabetes Care (2000) 23:979-983-
52. LANDIN-OLSSON M, BROGARD JM, ERIKSSON J, RASMUSSEN M, CLAUSON P: The efficacy of repaglinide administered in combination with bedtime NPH-insulîn in patients with Type 2 diabetes. A randomised, semi-blind, parallel-group, multi-centre trial. Diabetes (1999) 48(Suppl. 1):A0503-